Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Equities research analysts at Chardan Capital lowered their FY2025 earnings estimates for shares of Krystal Biotech in a report released on Tuesday, November 5th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of $5.78 for the year, down from their prior estimate of $8.69. Chardan Capital currently has a "Buy" rating and a $208.00 target price on the stock. The consensus estimate for Krystal Biotech's current full-year earnings is $2.88 per share.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company had revenue of $83.84 million during the quarter, compared to analyst estimates of $82.94 million. During the same period last year, the business earned ($0.67) earnings per share. Krystal Biotech's revenue was up 879.9% compared to the same quarter last year.
A number of other brokerages have also recently weighed in on KRYS. Cantor Fitzgerald restated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Citigroup raised their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday. HC Wainwright restated a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Tuesday. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Finally, Evercore ISI increased their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the company an "outperform" rating in a report on Monday, August 12th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $197.00.
Check Out Our Latest Report on KRYS
Krystal Biotech Trading Up 6.1 %
Shares of NASDAQ:KRYS traded up $11.26 during mid-day trading on Friday, reaching $196.71. The stock had a trading volume of 178,274 shares, compared to its average volume of 329,248. The business's 50 day moving average price is $181.20 and its 200 day moving average price is $180.29. Krystal Biotech has a 1 year low of $93.95 and a 1 year high of $219.34. The company has a market cap of $5.65 billion, a P/E ratio of 104.77 and a beta of 0.82.
Hedge Funds Weigh In On Krystal Biotech
A number of hedge funds have recently modified their holdings of KRYS. Segall Bryant & Hamill LLC raised its holdings in shares of Krystal Biotech by 352.4% in the third quarter. Segall Bryant & Hamill LLC now owns 157,144 shares of the company's stock valued at $28,605,000 after buying an additional 122,407 shares during the last quarter. Quest Partners LLC increased its holdings in shares of Krystal Biotech by 264.1% in the third quarter. Quest Partners LLC now owns 1,398 shares of the company's stock valued at $254,000 after purchasing an additional 1,014 shares during the period. Swiss National Bank raised its stake in shares of Krystal Biotech by 8.0% during the third quarter. Swiss National Bank now owns 39,100 shares of the company's stock worth $7,117,000 after purchasing an additional 2,900 shares during the last quarter. Huntington National Bank grew its position in Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company's stock valued at $104,000 after buying an additional 283 shares during the last quarter. Finally, KBC Group NV increased its stake in Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company's stock valued at $117,000 after buying an additional 132 shares during the period. 86.29% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Krystal Biotech
In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.10% of the company's stock.
About Krystal Biotech
(
Get Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Featured Stories
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
